Avidicure CEO Arthur Lahr spoke with Nuala Moran of BioWorld News about their $50M seed funding and how AVC-Boosters are designed to activate multiple immune pathways, unlocking powerful responses across both the innate and adaptive immune system. Read the full article to learn how they’re rethinking antibody engineering: https://bit.ly/4kNiZdY
News Apr 14, 2026
Richard C.A. Sainson, PhD, experienced R&D executive and scientific leader with demonstrated track record, appointed Chief...